GLP-1 Receptor Agonists Linked to Rare Eye Complications in Diabetic Patients

A recent case series has reported nine patients who developed ophthalmic complications while using glucagon-like peptide 1 (GLP-1) receptor agonists semaglutide and tirzepatide. The most common complication was nonarteritic anterior ischemic optic neuropathy (NAION), with seven patients experiencing this condition. Researchers believe that rapid correction of hyperglycemia induced by these drugs may be associated with … Read more

Ancient Plesiosaur Fossil Yields Rare Skin Remains

A 183-million-year-old plesiosaur skeleton from southern Germany has provided unique insights into the ancient marine reptile’s appearance and biology. The fossil, found in the Early Jurassic Posidonia Shale formation, boasts well-preserved skin traces around the tail and front flipper. Plesiosaurs were iconic Mesozoic creatures that dominated the world’s oceans 235-66 million years ago. Characterized by … Read more

AI News Summaries Found to Have Significant Inaccuracies

A BBC study has found that more than half of the AI-generated news summaries from popular chatbots struggled with factual inaccuracies and distortions. The research, which examined four major AI models, discovered that 51% of responses contained “significant issues,” while 19% included incorrect statements and dates. The study tested the accuracy of OpenAI’s ChatGPT, Google … Read more

Trump’s Interview with Bret Baier Descends into Chaos

In an interview with Fox News host Bret Baier, former President Donald Trump went on a rambling tangent, showcasing his characteristic inability to stick to simple questions. The conversation quickly devolved into self-congratulatory remarks, as Trump boasted about his supposed “great weaving” ability. During the interview, Trump skillfully sidestepped queries on inflation and national unity, … Read more

DuPont Shares Surge on AI-Driven Earnings Boost

DuPont’s shares jumped 7% Tuesday on better-than-expected earnings and revenue, driven by strong growth in its artificial intelligence semiconductor business. The company reported a 6.7% year-over-year increase in net sales to $3.09 billion, beating estimates of $3.07 billion. Adjusted earnings per share (EPS) rose 29.9%, the best quarterly growth rate since 2021. The stock’s positive … Read more

Anduril to Manage Microsoft Goggles for US Army Project

Anduril Industries, a drone maker and software developer, will take over managing the production of the US Army’s new infantry goggles currently being developed with Microsoft Corp. The deal, announced on Tuesday, comes as part of a larger defense technology project that could be worth more than $20 billion if all options are exercised. The … Read more

Jets Embark on Fresh Start as Aaron Rodgers Leaves

The New York Jets are starting anew under their new coach (Aaron Glenn) and general manager (Darren Mougey), who have revamped their staffs. The team is expected to find a new quarterback, moving beyond Aaron Rodgers. Several options could be explored: In-house candidate Tyrod Taylor has the respect of his teammates but concerns about durability … Read more

Wisconsin Dairy Farmers Face Uncertain Future Over Immigration Crackdown

The US government’s decision to target undocumented immigrants in dairy farms across the country has sent shockwaves through Wisconsin’s agricultural community. The state, which is home to some of the largest dairy producers in the US, is bracing for a significant impact on its dairy industry. According to insiders, thousands of immigrant workers who hold … Read more

Scientists Uncover Plesiosaur’s Secret Scales for First Time

A team of scientists has made a groundbreaking discovery in the study of soft tissue from ancient plesiosaurs, a type of marine reptile that lived during the time of dinosaurs. The 183-million-year-old fossil, known as MH7, was finally assembled and prepared for study in 2020 after being buried in a German museum garden since World … Read more

Novartis Buys Anthos for $925 Million, Adds Clot-Busting Prospect

Novartis has acquired Anthos Therapeutics for $925 million upfront to add the anti-factor XI/XIa antibody abelacimab to its late-phase pipeline. The deal includes up to $2.15 billion in regulatory and sales milestones. Abelacimab, an alternative to current anticoagulants like Xarelto, aims to stop blood clot formation without increasing the risk of bleeding. Anthos had shown … Read more